Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti CD19/CD22 chimeric antigen receptor T cell therapy - Hebei Senlang Biotechnology

Next Previous
Drug Profile

Anti CD19/CD22 chimeric antigen receptor T cell therapy - Hebei Senlang Biotechnology

Alternative Names: Anti-CD19/Anti-CD22 CAR-T cell therapy - Hebei Senlang Biotechnology; Senl_H19x22; SL19+22 CAR-T cell therapy - Hebei Senlang Biotechnology

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebei Senlang Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • No development reported Haematological malignancies

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Haematological-malignancies(Recurrent, Refractory metastatic disease) in China (Parenteral, Injection)
  • 14 Nov 2024 Phase-I/II clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (In adolescents, In children, In adults, In the elderly) in China (Infusion) (NCT06880913)
  • 08 Jun 2023 Updated efficacy and adverse events data from a phase I/II clinical trials in Non-Hodgkin's lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top